Is it better to use a live attenuated or inactivated influenza vaccine?

Generally speaking, there is no definitive way to determine whether the live attenuated or inactivated approach is superior regarding flu vaccines, as each has its own characteristics. A detailed analysis is as follows:

Inactivated influenza vaccines are produced by inactivating the influenza virus while retaining its immunogenicity. These vaccines are primarily used to prevent illnesses caused by types A, B, and C influenza viruses, including symptoms such as the common cold, tracheitis, and pneumonia. They are suitable for a broad population, including the elderly, infants, young children, and high-risk individuals with underlying medical conditions. After receiving an inactivated influenza vaccine, the human body typically develops protective antibodies within 2 to 4 weeks, effectively preventing infection by the influenza virus.

Live attenuated influenza vaccines contain viruses whose virulence has been weakened, but which still retain some degree of activity. These vaccines are administered via nasal spray containing the attenuated virus that cannot cause disease but can stimulate the immune system to produce a response. Because the virus still maintains partial activity, the safety profile of live attenuated vaccines may be slightly lower compared to inactivated vaccines. Additionally, currently available live attenuated influenza vaccines are mainly administered as nasal sprays, which may not be suitable for individuals with nasal sensitivities.

It is recommended to receive the most up-to-date influenza vaccine annually to maintain protection against newly emerging viral strains. The choice of which vaccine to use should be based on individual circumstances and made in consultation with a healthcare provider.